Impact of Preformed Donor-Specific Anti-HLA-Cw and Anti-HLA-DP Antibodies on Acute Antibody-Mediated Rejection in Kidney Transplantation

Transpl Int. 2023 Nov 22:36:11416. doi: 10.3389/ti.2023.11416. eCollection 2023.

Abstract

Given the risk of rejection, the presence of preformed donor specific antibodies (DSA) contraindicates transplantation in most allocation systems. However, HLA-Cw and -DP DSA escape this censorship. We performed a multicentric observational study, in which the objective was to determinate risk factors of acute antibody-mediated rejection (aABMR) in recipients transplanted with preformed isolated Cw- or DP-DSA. Between 2010 and 2019, 183 patients were transplanted with a preformed isolated Cw- or DP-DSA (92 Cw-DSA; 91 DP-DSA). At 2 years, the incidence of aABMR was 12% in the Cw-DSA group, versus 28% in the DP-DSA group. Using multivariable Cox regression model, the presence of a preformed DP-DSA was associated with an increased risk of aABMR (HR = 2.32 [1.21-4.45 (p = 0.001)]) compared with Cw-DSA. We also observed a significant association between the DSA's MFI on the day of transplant and the risk of aABMR (HR = 1.09 [1.08-1.18], p = 0.032), whatever the DSA was. Interaction term analysis found an increased risk of aABMR in the DP-DSA group compared with Cw-DSA, but only for MFI below 3,000. These results may plead for taking these antibodies into account in the allocation algorithms, in the same way as other DSA.

Keywords: HLA-Cw; HLA-DP; acute antibody-mediated rejection; donor-specific antibodies; kidney transplant.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Antibodies
  • Graft Rejection
  • Graft Survival
  • HLA Antigens
  • Histocompatibility Testing
  • Humans
  • Kidney Transplantation* / adverse effects
  • Tissue Donors

Substances

  • Antibodies
  • HLA Antigens